We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-8 of 8

Apotex Inc. v. Pfizer Ireland Pharmaceuticals (2010 FC 968)
  • Gowling WLG
  • Canada
  • October 27 2010

Apotex appealed an Order of Prothonotary Aalto dismissing a motion to strike parts of Pfizer’s Statement of Defence relating to res judicata, estoppel (issue and collateral), comity and abuse of process.


Novo Nordisk v. Cobalt Pharmaceuticals, S. 55.2 proceeding, Repaglinide, Aug. 3, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Cobalt served a NOA with respect to repaglinide, the S enantiomer of a previously disclosed racemic compound (the “388 compound”), alleging invalidity of the '851 patent on grounds of anticipation, obviousness and s. 53(1).


Sandoz Canada v Abbott Laboratories, appeal and cross-appeal of PMNOC decision, Clarithromycin extended-release, June 22, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Sandoz served a notice of allegation ("NOA") upon Abbott and filed an Abbreviated New Drug Submission ("ANDS") with respect to clarithromycin extended-release.


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling WLG
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm.


Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record.


Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal
  • Gowling WLG
  • Canada
  • May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board.


Scott E. Foster
  • Gowling WLG